Click here to close
Hello! We notice that you are using Internet Explorer, which is not supported by Xenbase and may cause the site to display incorrectly.
We suggest using a current version of Chrome,
FireFox, or Safari.
???displayArticle.abstract??? Smad4 is an essential signal transducer of the transforming growth factor beta (TGF-beta) signalling pathway and has been identified as a tumour suppressor, being mutated in approx. 50% of pancreatic cancers and approx. 15% of colorectal cancers. Two missense mutations in the C-terminal domain of Smad4, D351H (Asp351-->His) and D537Y (Asp537-->Tyr), have been described recently in the human colorectal cancer cell lines CACO-2 and SW948 respectively [Woodford-Richens, Rowan, Gorman, Halford, Bicknell, Wasan, Roylance, Bodmer and Tomlinson (2001) Proc. Natl. Acad. Sci. U.S.A. 98, 9719-9723]. Previous work in vitro suggested that only Asp-351 was required for interaction with Smad2 [Wu, Fairman, Penry and Shi (2001) J. Biol. Chem. 276, 20688-20694]. In the present study, we investigate the functional consequences of these point mutations in vivo. We demonstrate that neither of these colorectal cancer cells undergo growth arrest in response to TGF-beta, which can be explained, at least in part, by their inability to up-regulate cyclin-dependent kinase inhibitors p21 (CIP1 ) or p15 ( INK4b) after TGF-beta stimulation. Although the point-mutated Smad4s are expressed at normal levels in these colorectal cancer cells, they cannot interact with either TGF-beta-induced phosphorylated Smad2 or Smad3. As a result, these Smad4 mutants do not accumulate in the nucleus after TGF-beta stimulation, are not recruited to DNA by relevant Smad-binding transcription factors and cannot generate transcriptionally active DNA-bound complexes. Therefore both these colorectal tumour cells completely lack functional Smad4 activity owing to the missense mutations. Given the location of these mutations in the three-dimensional structure of the Smad4 C-terminal domain, the results also give us significant insights into Smad complex formation.
Angel,
12-O-tetradecanoyl-phorbol-13-acetate induction of the human collagenase gene is mediated by an inducible enhancer element located in the 5'-flanking region.
1987, Pubmed
Angel,
12-O-tetradecanoyl-phorbol-13-acetate induction of the human collagenase gene is mediated by an inducible enhancer element located in the 5'-flanking region.
1987,
Pubmed
Bardwell,
The POZ domain: a conserved protein-protein interaction motif.
1994,
Pubmed
Chen,
A transcriptional partner for MAD proteins in TGF-beta signalling.
1996,
Pubmed
,
Xenbase
Dai,
Transforming growth factor-beta responsiveness in DPC4/SMAD4-null cancer cells.
1999,
Pubmed
Datto,
Functional analysis of the transforming growth factor beta responsive elements in the WAF1/Cip1/p21 promoter.
1995,
Pubmed
Dennler,
Direct binding of Smad3 and Smad4 to critical TGF beta-inducible elements in the promoter of human plasminogen activator inhibitor-type 1 gene.
1998,
Pubmed
Derynck,
TGF-beta signaling in tumor suppression and cancer progression.
2001,
Pubmed
Faure,
Endogenous patterns of TGFbeta superfamily signaling during early Xenopus development.
2000,
Pubmed
,
Xenbase
Fink,
Transforming growth factor-beta-induced growth inhibition in a Smad4 mutant colon adenoma cell line.
2001,
Pubmed
Germain,
Homeodomain and winged-helix transcription factors recruit activated Smads to distinct promoter elements via a common Smad interaction motif.
2000,
Pubmed
,
Xenbase
Hahn,
DPC4, a candidate tumor suppressor gene at human chromosome 18q21.1.
1996,
Pubmed
Hannon,
p15INK4B is a potential effector of TGF-beta-induced cell cycle arrest.
1994,
Pubmed
Inman,
Nucleocytoplasmic shuttling of Smads 2, 3, and 4 permits sensing of TGF-beta receptor activity.
2002,
Pubmed
Inman,
Stoichiometry of active smad-transcription factor complexes on DNA.
2002,
Pubmed
,
Xenbase
Kim,
Autoinduction of transforming growth factor beta 1 is mediated by the AP-1 complex.
1990,
Pubmed
Koradi,
MOLMOL: a program for display and analysis of macromolecular structures.
1996,
Pubmed
Liu,
Dual role of the Smad4/DPC4 tumor suppressor in TGFbeta-inducible transcriptional complexes.
1997,
Pubmed
,
Xenbase
Massagué,
TGFbeta signaling in growth control, cancer, and heritable disorders.
2000,
Pubmed
Massagué,
Transcriptional control by the TGF-beta/Smad signaling system.
2000,
Pubmed
Maurice,
Loss of Smad4 function in pancreatic tumors: C-terminal truncation leads to decreased stability.
2001,
Pubmed
,
Xenbase
Morén,
Functional consequences of tumorigenic missense mutations in the amino-terminal domain of Smad4.
2000,
Pubmed
Müller,
Smad4 induces the tumor suppressor E-cadherin and P-cadherin in colon carcinoma cells.
2002,
Pubmed
Nakao,
TGF-beta receptor-mediated signalling through Smad2, Smad3 and Smad4.
1997,
Pubmed
,
Xenbase
Nicolás,
Epithelial to mesenchymal transition in Madin-Darby canine kidney cells is accompanied by down-regulation of Smad3 expression, leading to resistance to transforming growth factor-beta-induced growth arrest.
2003,
Pubmed
Nicolás,
Attenuation of the TGF-beta-Smad signaling pathway in pancreatic tumor cells confers resistance to TGF-beta-induced growth arrest.
2003,
Pubmed
Pertovaara,
Enhanced jun gene expression is an early genomic response to transforming growth factor beta stimulation.
1989,
Pubmed
Pierreux,
Transforming growth factor beta-independent shuttling of Smad4 between the cytoplasm and nucleus.
2000,
Pubmed
,
Xenbase
Reynisdóttir,
Kip/Cip and Ink4 Cdk inhibitors cooperate to induce cell cycle arrest in response to TGF-beta.
1995,
Pubmed
Schutte,
DPC4 gene in various tumor types.
1996,
Pubmed
Schwarte-Waldhoff,
Smad4/DPC4-mediated tumor suppression through suppression of angiogenesis.
2000,
Pubmed
Shi,
A structural basis for mutational inactivation of the tumour suppressor Smad4.
1997,
Pubmed
Wakefield,
TGF-beta signaling: positive and negative effects on tumorigenesis.
2002,
Pubmed
Watanabe,
Regulation of intracellular dynamics of Smad4 by its leucine-rich nuclear export signal.
2000,
Pubmed
Wisotzkey,
Medea is a Drosophila Smad4 homolog that is differentially required to potentiate DPP responses.
1998,
Pubmed
Wong,
Smad3-Smad4 and AP-1 complexes synergize in transcriptional activation of the c-Jun promoter by transforming growth factor beta.
1999,
Pubmed
Woodford-Richens,
SMAD4 mutations in colorectal cancer probably occur before chromosomal instability, but after divergence of the microsatellite instability pathway.
2001,
Pubmed
Wu,
Formation of a stable heterodimer between Smad2 and Smad4.
2001,
Pubmed
Wu,
Crystal structure of a phosphorylated Smad2. Recognition of phosphoserine by the MH2 domain and insights on Smad function in TGF-beta signaling.
2001,
Pubmed
Xiao,
An extended bipartite nuclear localization signal in Smad4 is required for its nuclear import and transcriptional activity.
2003,
Pubmed
Xu,
Smad2 nucleocytoplasmic shuttling by nucleoporins CAN/Nup214 and Nup153 feeds TGFbeta signaling complexes in the cytoplasm and nucleus.
2002,
Pubmed
Xu,
Mutations in the tumor suppressors Smad2 and Smad4 inactivate transforming growth factor beta signaling by targeting Smads to the ubiquitin-proteasome pathway.
2000,
Pubmed
Yeo,
The role of FAST-1 and Smads in transcriptional regulation by activin during early Xenopus embryogenesis.
1999,
Pubmed
,
Xenbase